November 22, 2024

Universität Heidelberg with 15 “Highly Cited Researchers

Universität Heidelberg with 15 “Highly Cited Researchers

International evaluation names researchers whose publications have been most cited worldwide

15 researchers from Heidelberg University feature on the recently published list of “Highly Cited Researchers”. This international evaluation names researchers whose publications have been cited most frequently worldwide in their respective field or who have an outstanding track-record of publications across several disciplines.

The list includes a total of 20 disciplines from the natural, life and social sciences as well as the cross-field category, which recognizes researchers with an outstanding track-record of publications across several disciplines. Ten of the 15 most-cited scientists from Ruperto Carola are in this 21st category. Among them is Prof. Dr Ralf Bartenschlager, who is on the list of “Highly Cited Researchers” for the twelfth time in a row. 

The citation count reflects how often colleagues cite a publication in their research papers, and is therefore an important indicator of a publication’s scientific influence. The latest list of highly cited researchers, issued by analytics company Clarivate, assessed publications between 2013 and 2023. 

Highly cited publications are those in the top 1 percent by citations in their respective field and year of publication. The list was first issued in 2001; it was revised for the first time in 2014 and since then has appeared annually. It currently comprises almost 6,900 designations of researchers from 59 countries.

Overview of highly cited researchers

Prof. Dr Simon Anders (biology / biochemistry)
Heidelberg University, Faculty of Biosciences
Leader of the “Biostatistics for Omics Data” research group at the BioQuant Center of Heidelberg University

Prof. Dr Dr Tobias Banaschewski (cross-field)
Heidelberg University, Medical Faculty Mannheim
Deputy Director of the Central Institute of Mental Health, Mannheim, and Medical Director of its Clinic of Child and Adolescent Psychiatry and Psychotherapy

Prof. Dr Ralf Bartenschlager (cross-field)
Heidelberg University, Medical Faculty Heidelberg
Head of the Molecular Virology division at the Center for Infectious Diseases of Heidelberg University Hospital and head of the Division of Virus-associated Carcinogenesis at the German Cancer Research Center

Prof. Dr Andreas von Deimling (neuroscience and behaviour)
Heidelberg University, Medical Faculty Heidelberg
Medical Director of the Department of Neuropathology at the Institute of Pathology of Heidelberg University Hospital

Prof. Dr Tobias P. Dick (cross-field)
Heidelberg University, Faculty of Biosciences
Head of the Division of Redox Regulation at the German Cancer Research Center

Prof. Dr Uwe Haberkorn (clinical medicine)
Heidelberg University, Medical Faculty Heidelberg
Medical Director of the Department of Nuclear Medicine at the Radiological Clinic of Heidelberg University Hospital and head of the Clinical Cooperation Unit Nuclear Medicine at the German Cancer Research Center

Dr Clemens Kratochwil (clinical medicine)
Heidelberg University, Medical Faculty Heidelberg
Senior physician in the Department of Nuclear Medicine at the Radiological Clinic of Heidelberg University Hospital

Prof. Dr Andreas Linkermann (cross-field)
Heidelberg University, Medical Faculty Mannheim
Director of Medical Clinic V and head of the Transplant Center at the University Hospital Mannheim

Dr Frauke Mücksch (cross-field)
Heidelberg University, Medical Faculty Heidelberg
Head of a Schaller Research Group in the Virology division at the Center for Infectious Diseases of Heidelberg University Hospital

Prof. Dr Klaus-Armin Nave (cross-field)
Heidelberg University, Faculty of Biosciences
Director of the Department of Neurogenetics at the Max Planck Institute for Multidisciplinary Sciences, Göttingen

Dr Dylan Nelson (space science, astrophysics in this context)
Heidelberg University, Faculty of Physics and Astronomy
Leader of the “Computational Galaxy Formation and Evolution” Emmy Noether Junior Research Group at the Institute of Theoretical Astrophysics, which is part of the Centre for Astronomy of Heidelberg University

Prof. Dr Michael Platten (cross-field)
Heidelberg University, Medical Faculty Mannheim
Director of the Department of Neurology of Mannheim University Hospital and member of the Translational Neuroscience research focus at the Medical Faculty Mannheim of Heidelberg University; head of the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center

Prof. Dr Julio Saez-Rodriguez (cross-field)
Heidelberg University, Medical Faculty Heidelberg
Director of the Institute for Computational Biomedicine at the Medical Faculty Heidelberg; 
research group leader in the Molecular Medicine Partnership Unit between the Medical Faculties of Heidelberg University and the European Molecular Biology Laboratory (EMBL); Head of Research at EMBL’s European Bioinformatics Institute in Hinxton (UK)

Prof. Dr Rolf-Detlef Treede (neuroscience and behaviour)
Heidelberg University, Medical Faculty Mannheim
Former head of the Department of Neurophysiology at the Medical Faculty Mannheim of Heidelberg University

Prof. Dr Wolfgang Wick (cross-field)
Heidelberg University, Medical Faculty Heidelberg
Spokesperson of the Head Hospital (Centre) of Heidelberg University Hospital as well as Managing Director of its Department of Neurology and Medical Director of Neurology and Polyclinic; head of the Clinical Cooperation Unit Neurooncology at the German Cancer Research Center

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp